Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 328

Sort by

Sort Order Select

Journal Articles

Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab

Bridget Austin, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Sheila Pierson, Larissa Borys, Kayla McHugh, Abiola Irvine, Kelley Dacus, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan Lim, Gordan Srkalovic, Frits van Rhee, Joshua Brandstadter, David Fajgenbaum

Blood (2025) 146 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2025-3009

Published: 2025

Journal Articles

Transcriptomic and pathological insights into PI3K–Akt pathway activation in idiopathic multicentric castleman disease, tafro and NOS subtypes

Tomoka Haratake, Midori Filiz Nishimura, Asami Nishikori, Yoshito Nishimura, Michael Gonzalez, Daisuke Ennishi, Manaka Tsunoda, David Fajgenbaum, Frits van Rhee, Shuji Momose, Yasuharu Sato

Blood (2025) 146 (Supplement 1): 4782.

https://doi.org/10.1182/blood-2025-4782

Published: 2025

Journal Articles

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network.

Syed Naqvi, Ejaz Shah, Firas Jafri, Manpreet Saini, Syed Abutalib, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Samer Al Hadidi, Frits van Rhee

Blood (2025) 146 (Supplement 1): 7597.

https://doi.org/10.1182/blood-2025-7597

Published: 2025

Journal Articles

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.

Syed Naqvi, Manpreet Saini, Ejaz Shah, Firas Jafri, Syed Abutalib, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee

Blood (2025) 146 (Supplement 1): 7595.

https://doi.org/10.1182/blood-2025-7595

Published: 2025

Journal Articles

Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease

Jean-Francois Rossi, Azhaar Ashraf, Yildiz Kelahmetoglu, David Fajgenbaum, Saishravan Shyamsundar, Frits van Rhee

Blood (2025) 146 (Supplement 1): 4788.

https://doi.org/10.1182/blood-2025-4788

Published: 2025

Journal Articles

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Raja Prince-Eladnani, Ajay Nooka, David Vesole, Barry Paul, Parameswaran Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin Van Vliet, David Siegel, Saad Usmani, Frits van Rhee

Blood (2025) 146 (Supplement 1): 2220.

https://doi.org/10.1182/blood-2025-2220

Published: 2025

Journal Articles

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors

Hira Cheema, Asis Shrestha, Syed Naqvi, Sanjay Muttineni, Sasya Dronavalli, Jawad Alrawabdeh, Marah Alzubi, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy, Jr, Fenghuang Zhan, Carolina Schinke, Frits van Rhee, Samer Al Hadidi

Blood (2025) 146 (Supplement 1): 4599.

https://doi.org/10.1182/blood-2025-4599

Published: 2025

Journal Articles

Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum

David E Mery, Samer Al Hadidi, Clyde Bailey, Eric Siegel, Hongwei Xu, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2025) 146 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2025-2172

Published: 2025

Journal Articles

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network

Syed Naqvi, Ejaz Shah, Firas Jafri, Syed Muhammad Ali Najafi, Manpreet Saini, Syed Abutalib, Maurizio Zangari, Frits van Rhee, Ankur Varma

Blood (2025) 146 (Supplement 1): 7247.

https://doi.org/10.1182/blood-2025-7247

Published: 2025

Journal Articles

Comparable response rates to therapies in idiopathic multicentric castleman disease patients with and without expert-confirmed diagnoses

Larissa Borys, Bridget Austin, Mary Jo Lechowicz, Sheila Pierson, Kayla McHugh, Abiola Irvine, Kelley Dacus, Adam Bagg, Daisy Alapat, Amy Chadburn, Megan Lim, Gordan Srkalovic, Frits van Rhee, Joshua Brandstadter, David Fajgenbaum

Blood (2025) 146 (Supplement 1): 6569.

https://doi.org/10.1182/blood-2025-6569

Published: 2025

Journal Articles

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor

Kayla McHugh, Yuan Huang, Bridget Austin, Larissa Borys, Abiola Irvine, Daisy Alapat, Adam Bagg, Amy Chadburn, Mary Jo Lechowicz, Megan Lim, Gordan Srkalovic, Frits van Rhee, David Fajgenbaum, Lu Zhang, Joshua Brandstadter

Blood (2025) 146 (Supplement 1): 1228.

https://doi.org/10.1182/blood-2025-1228

Published: 2025

Journal Articles

Interferon-γ sparks inflammatory fire in Castleman disease

Frits van Rhee, David Fajgenbaum

Blood (2025) 146 (1): 5–7.

https://doi.org/10.1182/blood.2025029270

Published: 2025

Journal Articles

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Blood (2024) 144 (Supplement 1): 4729.

https://doi.org/10.1182/blood-2024-193583

Published: 2024

Journal Articles

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy, Jr, Fenghuang Zhan, Eric Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 3789.

https://doi.org/10.1182/blood-2024-204228

Published: 2024

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression

Catherine Ma, Fumou Sun, Clyde Bailey, Hongwei Xu, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2024-204135

Published: 2024

Journal Articles

Identification of Risk Factors for Myeloma Progression in African American Patients

David E. Mery, Yihao Zhan, Hongling Peng, Eric Siegel, Cody Ashby, Clyde Bailey, Catherine Ma, Hongwei Xu, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2024-212173

Published: 2024

Journal Articles

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T Mckay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin H van Vliet, David S. Siegel, Saad Z. Usmani, Frits van Rhee

Blood (2024) 144 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2024-209903

Published: 2024

Journal Articles

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Criswell L. M. Lavery, Adam Bagg, Mary Jo Lechowicz, Daisy V. Alapat, Amy Chadburn, Megan S Lim, Gordan Srkalovic, Frits van Rhee, Joshua D Brandstadter, David C. Fajgenbaum

Blood (2024) 144 (Supplement 1): 1156.

https://doi.org/10.1182/blood-2024-211190

Published: 2024

Journal Articles

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Nishanth Thalambedu, Jeffery Sawyer, Janet L Lukacs, Phil Farmer, Samer Al-Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Maurizio Zangari

Blood (2024) 144 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2024-211798

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab

Transcriptomic and pathological insights into PI3K–Akt pathway activation in idiopathic multicentric castleman disease, tafro and NOS subtypes

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network.

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.

Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors

Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network

Comparable response rates to therapies in idiopathic multicentric castleman disease patients with and without expert-confirmed diagnoses

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor

Interferon-γ sparks inflammatory fire in Castleman disease

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression

Identification of Risk Factors for Myeloma Progression in African American Patients

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only